anticip impact compel us
cut estim across board
downgrad sell hold lower estim across board
cut estim across board cro stock expect neg impact
clinic trial busi least next quarter declin stock somewhat
discount downgrad medpac sell believ impact due
custom base small biopharma revenue speak two industri expert believ
pandem impact site visit trial recruit studi start-up new busi award
maintain buy rate
histori doesnt tell us much look back past year broader econom market
setback necessarili think internet bubbl post fiscal crisi
particularli good baromet transpir cours next month cro
industri unchart water view immedi impact studi delay like slow
backlog burn dont see risk elev cancel
believ see slow new busi award sponsor work mitig
impact exist trial base convers pharma cro exec expect
pronounc impact believ return normal
unless anoth spike contagion would note best estim
obvious fluid situat see notabl improv contain april may could see
better estim time current situat progress throughout summer
fall could see downsid estim
risk opportun see potenti downsid medpac given exposur small
biopharma revenu highli depend fund environ charl river also
high biotech exposur revenu pre-clin work may see quit much disrupt
hard tell sure iqvia benefit analyt busi higher recur revenu
syneo could see extend risk commerci busi new drug approv slowdown
final dont believ see rebound compani expect
valuat stock anywher last month vs declin
investor alreadi start discount impact exclud medpac
estim right trade materi premium group trade ep estim
pt downgrad sell
pt reiter buy
pt reiter buy
pt reiter buy
pt reiter buy
iclr pt maintain hold
estim would line rang past year could wrong downsid impact last materi beyond
spill could wrong upsid recoveri trial award come back quickli
page
life-cycle clinic trial
excret
mechan action best dosag rout administr
dose toxic level
fda review nda
fda close monitor advers event seriou advers
event could lead chang label dosag
even addit black-box warn
page
treatment safe
side effect
safeti dose test
safeti efficaci
explor safeti
effect compar
phase clinic trial
submit nda fda
approv
test small number
test larger group
affect individu
dozen
test new wider
demograph
drug biolog
approv market
sale
evalu drug
biolog time
larg number patient
page
near term impact due
protocol deviat written submiss fda
regul may requir pre approv except
necessari elimin appar immedi hazard
delay trial start up
slowdown patient enrol hesit vs inabl
reduc fund trial
patient continu care larg affect
site allow monitor travel
intern close exist trial last patient last
site perform health screen cras/monitor
closur lead studi slowdown potenti halt
patient appoint cancel due site overload
suppli chain disrupt due exposur china
transmiss complex drug medic equip
fda allow delay data submiss
econs patient inform consent part
decentr trial introduc home visit facilit
local health set procedur
blood test
mail investig drug directli particip
fda allow lengthen expir date mitig
fda allow improv clinic infrastructur
page
model
impact busi metric
impact sponsor
impact
impact
impact
risk difficulti surround studi
start-up
commit much year
sponsor
impact pre-revenu co
could see impact across board
see result capit
preserv mode may limit
start-up cadenc new trial
like candid focu later
expect see instanc suppli
constraint disrupt data collect
capit could lead increas
cancel slower delay studi
expect sale effort
constrain broader
covid like intern
compani polici
accordingli
book across cro
book
result advers
impact revenu
expect
curtail new hire forese
opportunist
expect trial
activ normal time
view
page
unwil unabl
particip new
clinician charg
site may unabl
repriorit away
patient may
unabl unwil
continu
note book expect
particularli pre-revenu sponsor
reli exist new fund
believ consensu estim revis downward coverag believ market price
much alreadi result one rate chang sell hold despit ep target come believ
medp smid focu lend greater upside- downside- risk environ expect downsid
factset strh research million except per share data
factset strh research million except per share data
page
buy upsid
pt lower reiter buy expect clinic
segment under-perform alongsid peer commerci revenu may
headwind next year year drug approv cadenc stagnat
page
buy upsid
pt lower reiter buy estim
posit ramp think tabl
page
ia buy upsid
pt lower reiter buy im busi
well insul may even benefit softwar segment may
slower ramp momentum remain posit thu estim
 came overal ep estim least impact compar
given off-set segment
page
charl river buy pt upsid
pt lower reiter buy charl river high
biotech exposur revenu pre-clin work may see quit
much disrupt expect later stage high biotech exposur
hard tell sure
page
icon plc iclr hold pt upsid
iclr pt lower reiter hold expect
least amount disrupt estim cro view one
best consist perform pure focu servic said
think market continu give iclr credit limit upsid potenti thu
keep us hold
page
medpac sell hold downsid
pt lower rate downgrad sell hold
given impli downsid target believ expos
reset estim valuat multipl view yet fulli
captur recent market correct given exposur
small-cap space greater mix smaller less capit pre-revenu busi
exposur larg sponsor exclus focu higher margin full
servic busi high backlog burn rate believ attribut
tailwind expand macro environ faster revenu growth higher
margin peer handicap contract believ
play next year two thu expect would recogn
advers impact revenu margin
page
page
page
sandi draper statement growth seq growth gross gross restructur transact goodwil asset impairment- total cost oper total expens pre-tax incom tax expens tax epsbas dilut dilut share adjust metricsadjust net adjust growth ebitda adjust ebitda growth suntrust robinson humphrey research estim compani reportstick synha contract research organ
page
page
sandi draper statement reimburs direct gross gross oper interest expens incom foreign currenc gains/ loss expens total pre-tax incom tax expens tax incom equiti loss unconsolid net incom gaapbas dilut dilut share pro-forma adjustmentsadjust ebitda adjust ebitda net adjust net suntrust robinson humphrey research estim compani reportstickerpraha contract research organ
page
share upsid current strh factsetstrh scenariovalu contract research organ
page
sandi draper statement dollar y/i total gross depreci restructur merger related- impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap growth forma adjust ebitdaadjust margin robinson humphrey research estimatestick iqva contract research organ
page
 margin share upsid current impli strh factsetmodel contract research organ
page
sandi draper cfacharl river statement million growth sell gener amort intang oper net interest net includ vc incom incom tax minor vision incom incom tax minor minor incom continu incom loss discontinu busi net net incom share ep continu adjust resultsadjust oper margin dilut ep ex vc growth growthnet sale forma oper forma net forma forma oper continu oper oper adjust margin growth compani report suntrust robinson humphrey research estimatestickercrla contract research organ
page
margin share upsid current target strh iclr scenariostrh model contract research organ
page
icon plc incom statementsandi draper cfa million except per share data y/i cost reimburs gross gross margin charg incom interest incom incom provis incom provis incom tax nci- net weight avearg dilut weight averag non- reconciliationnon- dilut ep net non- non- net non- ep growth ebitdaoper incom margin oper compani report strh researchtickericlra incom statement contract research organ
page
page
sandi draper hold statement growth direct servic reimburs total direct gross margin servic gross margin oper margin expens pre-tax incom tax expens tax incom dilut share non-gaap metricsgaap net interest tax margin growth growth suntrust robinson humphrey research estim compani reportstick medpa contract research organ
compani mention note
sandi draper herebi certifi view express research report accur reflect person view subject
compani secur also certifi receiv direct indirect compens
exchang express specif recommend report
